Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
KING OF PRUSSIA, Pa., April 22, 2013 /PRNewswire/ -- Trevena, Inc. a clinical stage pharmaceutical company today announced that its President and CEO, Dr. Maxine Gowen will present at the 12th Annual Needham Healthcare Conference on May 1, 2013, 10:00am, at Grand Hyatt New York.
Dr. Gowen will provide a detailed overview of the company's most advanced clinical programs which include TRV027, a biased ligand for the treatment of acute heart failure, which is currently in Phase 2 studies, and TRV130, in Phase 1b studies for acute pain where intravenous therapy is needed. First-in-man study results on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers were recently presented at the American Academy of Neurology.
The complete slide presentation of Dr Gowen's presentation will be available on Trevena's website (www.trevenainc.com) under the About Trevena tab.
Dr. Gowen will be available for one-on-one meetings with the investment community during the conference. Please contact conference organizers to secure a meeting time.
About Trevena and Biased Ligands
Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines. GPCRs are the targets for at least one-third of modern medicinal products, and remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR, to unlock new biology and avoid drug adverse effects. The discovery platform is applicable to a wide range of druggable targets and diseases. Trevena is based in King of Prussia, Pennsylvania and is backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company.
CONTACT: Kimberly Minarovich, 917-533-3268, email@example.com
SOURCE Trevena, Inc.
Released April 22, 2013